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ABSTRACT 
 
The human gene Suppression of Tumorigenicity-18 (ST-18) encodes a zinc finger 
protein previously associated with breast carcinoma, however it may have an oncogenic 
role in the development of Inversion 16 leukemia (inv16). This project assayed the level 
of ST-18 in inv16 leukemic lines compared to unrelated cancer lines.  The data show that 
ST-18 is more highly expressed in an inv16 acute myeloid leukemic cell line (Me-1) 
compared to Kasumi-1 and U937 non-inv16 cancer lines. In addition, murine ST-18 was 
successfully cloned into plasmid vector pMSCV2.2 for use in future over-expression 
experiments. 
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BACKGROUND 
 
I. LEUKEMIA 
I.1 DESCRIPTION 
Leukemia is a specific type of cancer pertaining to white blood cells. It is the 
leading cause of death by disease in children and young adults between the ages of 0 and 
20 and accounts for approximately 33% of cancer cases in children. Despite its reputation 
for affecting the young, however, leukemia does not discriminate based on age. The 
disease can affect any age, any race, any gender, at any time (Leukemia Research, 2011). 
In the US, more than 30,000 new cases of leukemia are diagnosed every year, and adult 
onset accounts for 90% of the new cases (Xie Y et al., 2003). 
 
I.II TYPES  
Leukemia can be categorized into four types, according to the type of white blood 
cell affected and how quickly the disease develops and advances (Vachani, 2007). The 
four types include Acute Myelogenous Leukemia (AML), Chronic Myelogenous 
Leukemia (CML), Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic 
Leukemia (CLL). Types are considered acute when the white blood cells multiply very 
quickly (AML and ALL). In the chronic types of leukemia (CML and CLL), white blood 
cells multiply very slowly (Oncolink.org). In the myelogenous types of leukemia (AML 
and CML), myeloid cells, granulocytes and monocytes are affected. In the lymphocytic 
types of leukemia (ALL and CLL), lymphocytes are affected (Life Extension, 2011). 
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I.III CAUSES 
Leukemia is a specific type of cancer pertaining to white blood cells. White blood 
cells are made in the bone marrow and spend their lives traveling through the blood 
stream to other parts of the body to defend the body against infections. Normally, all cells 
in the body regardless of type are created and destroyed at the same rate. This rate can 
change, depending on what the body requires, but it is always a stable process, keeping 
the body balanced (Peterson, 2011). Leukemia occurs as a result of DNA damage to 
white blood cells (Reilly, 2004). One or more DNA mutations can disrupt this balanced 
process, causing cells to become damaged, mutated and cancerous. The type of cell 
affected by the mutation dictates the type of cancer. The DNA damage in leukemia is 
caused by chromosome translocations (shifting and re-arrangement of chromosome 
segments), mutations, or a combination of both (Irons and Stillman, 1996). The 
mutation(s) cause cell production in the bone marrow to go awry. The body starts to 
produce new abnormal white blood cells when they aren’t required and when they are not 
mature. The body arrests blood cell precursors, called “blasts”, before they can mature 
into blood cells capable of fighting infection (National Marrow Donor, 2011). The body 
also begins inappropriately restricting mature white blood cells from undergoing cell 
death, or “apoptosis” (Figure 1). The abnormal white blood cells gain the unique ability 
to divide or “proliferate” out of control. They quickly take over the bone marrow and 
spread to other tissues and organs in the body via the bloodstream, crowding out other 
healthy cells in their path (MayoClinic, 2011). The body’s bone marrow may also begin 
to make abnormal red blood cells and platelets (National Marrow Donor, 2011). 
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Figure 1: Comparison of Normal and Cancerous Cell 
Division. Normally, mutated cells undergo apoptosis 
(cell death) to eliminate them from the body (left panel), 
while cancerous cells (right panel) incorporate the 
mutation and acquire a cell proliferation advantage 
(diseaseeducation.com). 
 
 
 
 
 
II. AML AND INV(16) 
II.I DESCRIPTION 
Acute myeloid leukemia is the most common of the four types of leukemia. AML 
occurs in both children and adults, but is most common in adults over the age of 65 
(Mayo Clinic, 2010). AML affects the myeloid progenitor cells, which are normally 
capable of renewing themselves and of transforming, or “differentiating,” into red blood 
cells, white blood cells or platelets. DNA mutations arrest myeloid cells in an early stage 
of development, restricting maturation and causing an overabundance of young mutated 
cells incapable of fighting infections (National Marrow Donor, 2011). These young 
abnormal cells acquire a survival advantage and are able to proliferate uncontrollably, 
allowing them to crowd out the normal healthy cells.  
The types of mutations responsible for the abnormal cells are chromosomal 
 8 
translocations, chromosomal rearrangements and other genetic abnormalities (Mayo 
Clinic, 2010). Inversion 16 leukemia, or inv(16), is a specific type of leukemia marked by 
the rearrangement of chromosome 16. Inv(16)(p13;q22), is one of the most frequent 
recurring chromosomal rearrangements detected in AML, generally marked by abnormal 
bone marrow eosinophils, deregulated cell proliferation, impaired differentiation, and a 
survival advantage to leukemic cells (Grardel, 2002). 
 
II.II SPREAD 
After leukemic cells conquer the bone marrow, they begin to spread and 
proliferate to other parts of the body. Cell signaling is the most important director of 
leukemia cell spread. The abnormal cells move through the bloodstream and invade other 
organs, such as the spleen, lymph nodes, liver and central nervous system as a result of 
three contributing cell-signaling factors: growth factors, cytokines and contact inhibition 
(Life Extension, 2011). 
The body controls cell proliferation with a specific subset of signaling proteins 
called “growth factors.” Cells secrete growth factors, which bind to cell-surface receptors 
and stimulate cell growth, proliferation and “differentiation”, which refers to the 
capability of less-specialized cell types to become more specialized cell types (Prospec 
Protein Specialists, 2011). Research suggests that growth factors could have a role in the 
proliferation-aspect of cancer. 
Cytokines are another class of signaling proteins, many members of which also 
exhibit growth factor activity. They stimulate paracrine, autocrine and endocrine systems 
when secreted and are produced by hematopoietic and non-hematopoietic cell types. 
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Many types of leukemia produce specific inflammatory and immunosuppressive 
cytokines and use cell-signaling pathways early in the disease progression (Life 
Extension, 2011). The cytokines overexpressed in AML include vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF) and hepatocyte growth 
factor (HGF) (Life Extension, 2011). VEGF is considered necessary for growth, survival 
and spread of leukemic cells (Podar and Anderson, 2004).  bFGF is usually necessary in 
the spread of cancer cells (Bieker et al., 2003). Research shows that HGF is 
overexpressed in myelomonocytic leukemia (Aguayo et al., 2000). 
Contact inhibition also contributes to cell spread. In normal cells, contact 
inhibition is the phenomenon that signals normal cells to stop dividing. Cells discontinue 
replication when they recognize contact with adjacent cells. Research shows that cancer 
cells lack contact inhibition, which causes them to divide without regulation (Yongqing 
et al., 2010). 
II.III RISK FACTORS 
One predominant hypothesis is that all cancers begin with just one abnormal cell. 
This first cell becomes cancerous as a result of abnormal gene function most often caused 
by DNA mutations. In AML, a small proportion of cases are caused by inherited, 
abnormal genes (Fong and Brodeur, 1987; Bischof et al., 2001; Alter, 2003). Children 
with Down’s Syndrome, in particular, have a 10 to 20 time higher risk of developing 
leukemia than normal (Fong and Brodeur, 1987). However, most DNA damage is caused 
by sporadic mutations. These mutations are not inherited and are caused by lifestyle and 
environmental factors like weight, exercise, diet, and drug or alcohol use. 
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Excess weight causes the body to produce and circulate more hormones such as 
estrogen and insulin, which can stimulate cancer growth. Exercise helps control weight, 
and regulates hormone levels and immune system function. A compromised immune 
system cannot detect mutations or adequately direct apoptosis or replication in cells 
(American Cancer Society, 2011).  
A nutritious diet improves health, aids in weight control, and lowers risk of 
cancers. Insufficient amounts of micronutrients can cause DNA damage associated with 
leukemia. It can also limit the ability for repair (Ames, 1998; Ames, 1999). A diet high in 
fruits, vegetables and other antioxidants can help protect against DNA damage (Ames et 
al., 1993).  
Long-term drug use is also a risk-factor in developing AML. Alcohol use raises 
estrogen levels in the body, slows or hinders DNA repair, causes irritation, and acts as a 
solvent, helping harmful chemicals enter cells (American Cancer Society, 2011). 
Cigarettes contain leukemia-causing chemicals such as benzene (Korte, et al., 2000). 
Sporadic medical treatments can also cause DNA mutations, which lead to AML. 
The major cause of AML in children is chemotherapy for the treatment of other cancers 
(Felix, 1998).  Treatment-related AML accounts for up to 20 percent of AML cases 
(Kaldor, et al., 1990; Smith et al., 1996). High amounts of radiation have been linked to 
myeloid leukemia by inducing DNA damage through translocations (Kamada et al., 
1987; Archer, 1987). 
Aside from lifestyle choices, leukemia-causing DNA mutations can occur simply 
as a result of one’s passive environment. Environmental factors include medical 
treatments, pollution or silent chemicals present in the home or workplace (Irons and 
 11 
Stillman, 1996; Greaves, 2004). Long-term or occupational exposure to benzene is a 
cause of AML, as well as agricultural chemicals such as herbicides and pesticides (Austin 
et al., 1988; Meinert et al., 2000). Hair dyes also contain chemicals that are associated 
with AML (Sandler, 1995). 
Age is considered to be one of the biggest risk factors for developing AML. 
Seventy-percent of cases occur over the age of 50 (Fenech et al., 1997; Russell, 2000). 
Older people have more fragile chromosomes in their white blood cells, making them 
more susceptible to the types of DNA damage known to cause leukemia (Esposito et al., 
1989; Mendoza-Nunez et al., 1999). Older people with AML are also more difficult to 
treat, because older people are more resistant to chemotherapy (Schoch et al., 2001). 
 
II.IV TREATMENT OPTIONS 
 Acute myeloid leukemia progresses quickly. Immediate treatment is necessary to 
provide the best chance of remission. The treatment of AML is complex, and may include 
chemotherapy, radiation therapy, and bone marrow transplant. Chemotherapy and 
radiation are generally effective in treating AML, and are often used as concurrent 
treatments (Life Extension, 2011). Bone marrow transplantation mainly used as a last 
resort, since the treatment by itself shows 15% mortality, and it otherwise has serious side 
effects.  
Chemotherapy involves administering drugs that attack rapidly-dividing cells, like 
cancer cells. Chemotherapy agents stop the growth of these cells by either destroying 
them or keeping them from dividing. But cancer cells are not the only type of rapidly-
dividing cell in the body, so chemotherapy also attacks hair follicle cells, platelets, cells 
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lining the gastrointestinal tract and healthy blood cells (AP John Institute, 2011). This 
attack on normal, healthy cells contributes to some of the side effects of chemotherapy 
like hair-loss, fatigue, low blood cell counts, risk of infection, nausea and vomiting, loss 
of appetite, and diarrhea. 
 Radiation therapy kills cancer cells by exposing them to ionizing radiation, which 
damages cell DNA. There are two types of radiation therapy. The most common type of 
radiation treatment is called “external-beam radiation therapy.” This type of therapy 
involves giving radiation using a machine outside the body (AP John Institute, 2011). 
External-beam radiation therapy is used for AML that has or may spread to the brain and 
spinal cord and may also be used to treat bone pain that can occurs from high numbers of 
leukemia cells in the bone (Naveen et al., 2006; National Marrow, 2011). 
For some patients, a bone marrow transplant may offer the best chance for a long-
term remission. A bone marrow transplant involves chemotherapy followed by replacing, 
or “infusing,” the abnormal stem cells in the blood with donor stem cells (AP John 
Institute, 2011). These re-infused stem cells grow into and restore the body's blood cells. 
A transplant is a strong treatment with risks of serious side effects; it is not used for all 
patients with AML. A transplant is used when chemotherapy alone is unlikely to provide 
a long-term remission (National Marrow, 2011). Many patients with AML reach 
remission, but relapse is common. Most patients need a second phase of treatment to 
prevent relapse (National Marrow, 2011). 
 
II.V CAUSE AND MECHANISM 
At the genetic level, AML is the best understood of the acute leukemia family. 
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Figure 2: Diagram of the RTK/RAS Signaling Pathway Showing 
Mutation Sites in AML. A red asterisk indicates a known mutation 
site that causes AML. Note the key role of the FTL3 (c-Kit) receptor 
to affect the RAS/RAF pathway (Reilly, 2004). 
Research confirms that AML is caused by the collaboration between two types of DNA 
mutations: proliferative and blocking; either type of mutation alone is usually insufficient 
to cause AML (Reilly, 2004). Proliferative mutations give a proliferative or survival 
advantage to cells. Approximately 70% of patients with AML and inv(16) are known to 
possess proliferative mutations (Reilly, 2004). Research has shown that the proliferative 
and survival advantage of AML cells is due to a missing signal caused by mutations in 
either the receptor tyrosine kinase (RTK) class III or the RAS genes (Reilly, 2004). A 
variety of mutations may occur to cause this signaling disruption (Figure 2). Internal 
tandem duplications, and mutations in the tyrosine kinase domain (TKD) of the FLT3 
receptor, are the most common (Cammenga et al., 2005). Mutations may also affect other 
RTK, for example c-KIT. These mutations contribute to a small percentage of AML 
cases (Cammenga et al., 2005). 
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In inv16 leukemia, the inversion of chromosome 16 breaks and joins the CBFB 
gene with the myosin gene MYH11 to create a CBFB-MYH11 fusion protein. CBFB-
MYH11 encodes a fusion oncoprotein CBFB-SMMHC, which is present in 12% of AML 
cases (Kuo et al., 2006).  The expression of CBFB-MYH11 disrupts the normal 
transcription activity of the core binding factor (CBF) in AML and inv(16) leukemia. 
CBF is a family of heterodimeric transcription factors containing a common B subunit 
(CBFB) and a CBFα subunit, which is encoded by one of the three genes in the RUNX 
family (RUNX1, RUNX2 or RUNX3) (Kuo et al., 2006). CBF is an important 
transcriptional activator of genes involved in hematopoiesis and bone development 
(Takahashi et al., 1995; Komori T et al., 1997). Disruption of CBF by the CBFB-MYH11 
fusion gene impairs normal CBF activity. The CBFB-MYH11 fusion protein blocks 
embryonic hematopoiesis at the stem progenitor cell level and impairs differentiation 
(Kuo et al., 2006). 
The DNA binding alpha subunit in CBF is encoded by one of three RUNX 
members (RUNX1, RUNX2 or RUNX3). All three RUNX proteins are integral in 
pathways regulating cell growth and differentiation. Studies have shown that functional 
mutations in RUNX1 cause AML (Kuo et al., 2006) and 5-10% of AML cases involve 
somatic point mutations in RUNX1 (Blyth et al., 2005). 
 
III. ST18 
Suppression of tumorigenicity-18 (ST-18) is a transcription factor with mostly 
unknown function (Yang et al., 2008). Previous studies have established that ST-18 
represses transcription of a synthetic reporter construct consisting of the consensus 
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sequence AAAGTTT linked to the thymidine kinase promoter. ST18 is expressed at a 
low level in a number of normal tissues including mammary epithelial cells (Jandrig et 
al., 2004). Research has implicated ST-18 in breast cancer, where ST-18 exhibits 
significantly reduced expression (Yang et al., 2008). ST-18 has been identified as a 
possible gene involved in t(8;21) leukemia, however minimal research has been done 
regarding the role of ST18 in leukemia of other types (Steinbach et al., 2006). 
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PROJECT PURPOSE 
 
The human gene Suppression of Tumorigenicity-18 (ST-18) is a zinc finger 
protein previously associated with breast carcinoma, however it has recently been 
identified as having a possible oncogenic role in the development of Inversion 16 
leukemia (inv16). Despite this speculation, the extent of the role of ST18 in inv16 
leukemogenesis has yet to be determined.  The goal of this project was to study the 
expression and effect of ST-18 on cell survival, proliferation, and differentiation in inv16 
acute myeloid leukemic cells (Me-1) versus non-inv16 cancer cell lines (Kasumi-1 and 
U937) using gene knock-in and knock-out experiments. This report demonstrates that 
ST18 is more highly expressed in Me-1 cells compared to Kasumi-1 and U937 cell lines. 
This report also demonstrates that murine ST-18 was successfully cloned into vector 
pMSCV2.2 for use in future knock-in experiments. 
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METHODS 
 
CELL CULTURE 
Kasumi-1 cells were incubated in RPMI supplemented with 20% Fetal Bovine 
Serum (FBS) and 1% penicillin/streptomycin (p/s). U937 cells were incubated in RPMI 
supplemented with 10% FBS and 1% p/s.  Me-1 cells were incubated in RPMI 
supplemented by 20% FBS with 1% p/s and 2.5% HEPES.  All cells were incubated at 
37C. 
 
QUANTITATIVE REAL TIME -POLYMERASE CHAIN REACTION 
Approximately 1x10
6
 cells of each cell type were isolated by centrifugation. RNA 
isolation was accomplished with use of TRIZOL reagent, chloroform, RNA-free 
isopropyl alcohol, and RNA-free 75% ethanol.  RNA pellets were re-dissolved in 20 uL 
RNAse-free water. The RNA was synthesized into DNA using a mixture of random 
primers, dNTP, 5x First Strand buffer, DDT/DTT, RNAse out, SuperScript III RT added 
to 2 ug of RNA template. The cDNA was used for quantitative real time PCR using 
SYBR green and forward/reverse primers, to make 3 replicates per gene. The samples 
were run as a comparative CT (CT), at a ramp speed of 2 hours standard, using 
StepOne Software v2.1.  
 
VECTOR CONSTRUCTION 
RESTRICTION DIGESTS 
DNA samples (approximately 1-2 ug) were digested with appropriate restriction 
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enzyme(s), buffer, 10x BSA and H2O for a total reaction volume of 20 ul. Samples were 
incubated at 37C for 60 minutes. 
 
PCR GEL 
Electrophoresis gels were used to confirm that digestions or colony PCR results 
were complete and correct. The digested samples were mixed with 6x loading buffer and 
run in comparison to a DNA ladder. 
 
DNA PURIFICATION 
The digested vector DNA was purified using the QIAQuick PCR Purification kit, 
treated with SAP (to remove 5’ phosphate residues to prevent self-ligation) and 10xSAP 
buffer, and then re-purified.  
 
BLUNT END LIGATION 
The cDNA enzyme digest was mixed with Klenow DNA poly I added to dNTP 
and appropriate buffer for each enzyme and ddH2O, then incubated for 15 minutes at RT.  
 
LIGATION 
Using the digested cDNA samples, three types of ligation products were 
produced: one sample containing both vector and insert at a ratio of 1:6, one containing 
no insert, and one containing no ligase. Approximately 50 ng of vector and 2 ul 10x T4 
DNA ligase buffer were added to all three samples. Approximately 150 ng of insert was 
added to all samples except for the “no insert” sample, and 1 ul ligase was added to all 
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samples except for the “no ligase” sample. To each sample, water was added to make a 
reaction volume of 20 ul. Samples were incubated at RT for 60 minutes. 
 
TRANSFORMATION 
Each ligation product was added to a vial of 100 ul competent bacteria, and was 
incubated on ice for 30 minutes. The mixtures were heat shocked, 1 ml of LB broth was 
added to each sample, then all samples were incubated at 37C for 60 minutes in a 
shaker. The transformed ligation products were transferred to plates with ampicillin or 
kanamycin-containing media and incubated at 37C for approximately 16 hours. 
 
MINIPREP 
Bacterial cells were harvested from 5 mL cultures grown in a shaker at 37C for 
approximately 16 hours. The bacterial pellet was collected in a microcentrifuge, then 
buffers P2, P2 and N3 were all added according to the QIAGEN Plasmid DNA 
Purification kit.  The samples were microcentrifuged and the supernatants added to 
QIAprep spin columns, centrifuged again and resuspended in TE buffer. 
 
MIDIPREP 
A 250 mL bacterial culture containing ampicillin and 100 uL bacteria was 
incubated in a shaker for approximately 16 hours at 37C. The DNA from the resulting 
pellet was re-suspended, lysed and precipitated using a cocktail of kit-included buffers 
(P1, P2 and P3). The lysate was poured into a QIAfilter Cartridge, incubated at RT for 10 
minutes and then filtered through a Buffer QBT-equilibrated QIAGEN-tip 500. The DNA 
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was eluted in 15 mL of Buffer QF after the QIAGEN-tip was washed twice with 10 mL 
of Buffer QC.  The DNA was precipitated with RT isopropanol and the mixture was 
centrifuged at 15,000xg. The resulting DNA pellet was washed with 5 mL of RT 70% 
ethanol, centrifuged at 15,000xg for 10 minutes. This pellet was air-dried for 5 minutes 
and the DNA was re-dissolved in TE buffer. 
 
BACTERIAL CELL CULTURE 
Using sterile technique, transformed bacterial colonies were individually sampled 
using a micropipettor tip and grown in 5 mL of LB broth + ampicillin. All samples were 
incubated at 37C for approximately 16 hours in glass bacterial culture tubes. 
 
BACTERIAL COLONY PCR 
Specific colonies were sampled using a micropipettor tip, and grown on both 
kanamycin and ampicillin plates. Each PCR well contained bacteria, forward and reverse 
primers, dNTP, ThermoPol Buffer, Taq Polymerase and ddH2O for a reaction volume of 
20 ul. The plate was run through 30 cycles of temperatures and amounts of time (3 min. 
at 95C, 30 sec. at 94C, 30 sec. at 60C, 30 sec. at 72C, 10 min. at 74C, Forever at 
4C). 
 
TRANSFECTION 
cDNA samples Gag-Pol and VSVG were transformed, added to 250 mL of 
ampicillin-containing LB broth, and incubated overnight at 37C. After a midiprep was 
performed on Gag-Pol and VSVG, 1.67 ug of each ST18 group was added to 1.67 ug 
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gag-pol, 0.167 ug VSVG and buffer EC.  16 ul enhancer and 60 ul Effectene Transfection 
Reagent were added to each DNA enhancer mixture. Growth medium was added to each 
tube, and the transfection complexes were added drop-wise onto 293T cells in 60mm 
culture dishes. All dishes were incubated at 37C for approximately 18 hours. The 
medium was carefully collected at 7-9 hour intervals into 4 bottles for the four viruses. 
Each virus was vacuum-filtered and centrifuged at 4C for two hours. Each resulting 
pellet was re-suspended in new media, separated into 1.5 mL aliquots and stored at  
-80C. 
 
INFECTION 
8 ul Polybrene was added to 10 mL 293T cell medium. Three concentrations of 
virus and Polybrene media were mixed for each virus in 1.5 mL Eppendorf tubes: 1:1, 1:2 
and 1:4 (1:1: 0.6 mL virus, 0.6 Polybrene media, 0.3 mL regular media. 1:2: 0.3 mL 
virus, 0.6 mL Polybrene media, 0.3 mL regular media. 1:4: 0.15 mL virus, 0.6 mL 
Polybrene media, 0.45 regular media). 1 mL of each mixture was added to a 100 mm 
plate of 293T cells. After 5 hours, 4 mL regular medium was added to all cells. After 36 
hours, each plate was split and transferred to two wells of a 6-well plate. 3 mL of regular 
medium was added to each well, and then 2 ng Puromycin was added to one of the two 
wells of each virus at each concentration. Plates were incubated at 37C for 48 hours, 
after which the cells in each well were counted. 
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RESULTS 
 
The first goal of this project was to assay the expression of human ST-18 in an 
inv16 leukemia cell line (Me-1) versus other cancerous cell lines Kasumi-1 and U-937.  
The level of was determined using Quantitative Real Time PCR.  Kasumi-1 is a human 
acute myeloid leukemia cell line of the t(8;21) chromosome translocation, functioning as 
a comparative cancerous cell line for this assay (Asou et al., 1991). U-937 is a human 
diffuse histocytic lymphoma cell line, which displays model monocytic characteristics 
(atcc.org). This cell line serves as the control cell line in this assay. MSLN and CLIPR59 
are other genes known to exhibit cancer-related over-expression. CLIPR59 over-
expression, in particular, has been linked to inv16 cell lines (Bullinger et al., 2007). 
MSLN over-expression is already being used as a marker to diagnose mesotheliomas, 
ovarian cancers and pancreatic cancers (Hucl, 2007).  Therefore, the expression of MSLN 
and CLIPR59 were assayed for comparison. 
The data show that ST-18 mRNA expression (red histobars) is notably higher in 
Me-1 cells than in the control U-937 cell line (Figure 3).  Additionally, ST-18 expression 
is slightly higher in Me-1 cells than in the related cell line Kasumi-1. MSLN mRNA 
expression (green histobars) is down-regulated in Me-1 and Kasumi-1 cells, while 
CLIPR59 mRNA expression (violet histobars) is slightly up-regulated in Me-1 cells and 
down-regulated in Kasumi-1 cells (Figure 3). 
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Figure 3.  Assay of Relative Gene Expression in Various Cell Lines by 
qRT-PCR.  ST-18 (red histobars) is highly upregulated in Me-1 cells 
compared to control U937 cells. ST-18 is also upregulated in Kasumi-1 
cells, but to a lesser extent.  CLIPR59 (violet histobars) shows a mix of 
modest down and up-regulation depending on the cell line.  MSLN (green 
histobars), a marker for some types of cancer, is down-regulated in all cell 
lines. 
 
 
Based on the results of the qRT-PCR expression assay, the second goal of this 
project was to make a viral construct capable of over-expressing ST-18 to explore the 
effects of ST-18 over-expression in both non-leukemic and inv16 leukemic cells. 
Although the viral construct could not be finished in the timeframe allowed for this 
project, the murine ST-18 gene was successfully cloned into plasmid vector pMSCV2.2.   
Several potential ST-18-containing vectors were digested with SacI (Figure 4, Lanes 2-
5), identifying one positive clone (lane-4) that released bands of 7.1 kb, 0.35 kb, and 0.30 
kb. 
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Additional restriction digestions were performed on selected samples (Lanes 3, 4, 
and 5 from Figure 3) to confirm that the sample in Lane 4 contained the ST-18 insert 
(Figure 5).  Samples were digested with Dra1 (red lanes) and also double digested with 
Xho1/Acc1 (blue lanes). Dra I restriction sites predicted bands of 4.0Kb, two-2.3Kb, 
2.3Kb, and 0.04Kb in samples positive for the ST-18 insert, and one positive was 
observed (red lane-4).   The double digestion with XhoI/AccI predicted bands of 7.1Kb 
and 0.6Kb in samples positive for the ST-18 insert, and one was positive (blue Lane 4). 
Thus, one successful clone was positively identified using a total of three different 
restriction digestions schemes. 
Figure 4. Restriction Digestion Screening of 
Plasmid Vector pMSCV2.2+ST-18.  Samples were 
digested with SacI.  One sample was positive for ST-
18 insert, yielding bands of 7.1 Kb, 0.35 Kb and 
0.30 Kb (Lane 4). 
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Several attempts were made to sub-clone the insert from pMSCV2.2 + ST-18 into 
viral-based vectors several times, but no candidates contained both insert and vector.  
Ideally, our ST-18-containing vector could be used to sub-clone the murine ST-18 gene 
into a viral construct for use in future experiments when more time is allowed.  In spite of 
these results, we transfected a lentiviral construct with three ST-18 containing plasmids, 
and the preliminary screen yielded adequate cell numbers, however no cells survived in 
the Polybrene wells and the end of the screening process, suggesting that no live virus 
was produced. 
Figure 5.  Continued Restriction Digestion 
Screenings of Vector pMSCV2.2+ST-18.  
Samples were digested with DraI (red lanes) or 
XhoI/AccI (blue lanes). Samples positive for ST-18 
insert yielded bands of 3.0 Kb, 2.3 Kb(2) and 0.04 
Kb when cut with DraI (red Lane 4). Samples 
properly-containing ST-18 insert yielded bands of 
7.1 Kb and 0.6 Kb (blue Lane 4). 
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DISCUSSION 
 
The most reliable results of this paper came from the qRT-PCR expression 
analysis comparing ST-18 mRNA expression in Me-1 cells (containing the inv16 
leukemic mutation) versus Kasumi-1 and U937 cancer cell lines that do not contain the 
inv16 mutation.  Synthesizing cDNA from cells for RT-PCR was the most effective 
procedure of the methods used in this paper, as the procedure yielded significant results 
each time it was used.  ST-18 expression was markedly higher in inv16 leukemia cells 
(Me-1 cells) than in Kasumi-1 or U937 cells. This data widens the type of cancers 
involving ST-18 over-expression, connecting over-expression in breast cancer cell lines 
to over-expression in inv16 leukemia cells. Other interesting future experiments 
involving RT-PCR and ST-18 expression should include comparing ST-18 expression in 
other leukemia cell lines and in other un-related cancer cell types. 
The ST-18 DNA cloning procedures were the most challenging procedures in this 
project.  After numerous attempts, I was finally able to yield a positive clone containing 
the murine ST-18 gene inserted (in the correct orientation and in the correct number of 
copies) into plasmid pMSCV2.2.  The successful cloning of ST-18 into plasmid, and its 
proper orientation, was determined by three different restriction digestions.   
Many additional attempts were made to try to subclone the plasmid ST-18 insert 
into a viral-based vector to use it in further transfection/infection experiments. However, 
despite altering restriction enzymes, vector-to-insert ratios, and purification techniques, 
none of those attempts proved fruitful.  I determined that these obstacles are typical of the 
virus/DNA cloning process. This project revealed that while mastering techniques is 
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crucial to producing valid results, there are additional elements including constant 
repetition, procedural patience, and sometimes “luck” that make positive colonies with 
the correct orientation of genes.  More often than not, the ST-18 insert did not insert 
correctly in my experiments despite best efforts and care.  Repeated restriction digestions, 
ligation procedures and transformation procedures were repeated countless times to 
finally produce a single colony that correctly expressed ST-18. Part of the project’s 
success involved persevering with experiments despite the fact that the ST-18 insert 
procedure required perfection to yield perfect results. It was hard to accept that this 
aspect of the procedure was uncontrollable. 
In the transfection/infection experiment, no cells survived in the puromycin wells, 
suggesting that no intact virus was produced. There are several possible reasons for this.  
Since this procedure was only completed one time due to time constraints, it is likely that 
human error occurred. It’s possible that too much puromycin was added, killing all cells. 
Another explanation may be that the 293T cells responsible for producing the virus may 
have been killed by either not sufficiently warming up the cellular media before adding to 
the cells or by harvesting the virus after too long of a time period. Additionally, it was 
necessary to take several viral collections in the middle of the night. Fatigue might have 
been a negative factor that resulted in error. It was necessary to complete many of the 
procedures in this project at least once before achieving accurate results. Additional 
opportunities to complete this procedure may have yielded different, more significant 
results. My recommendation for future success is that students complete the 
transfection/infection experiments in groups of two to ensure accuracy and close, round-
the-clock monitoring that this procedure requires in order to achieve success. 
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The unique design of this project would suit two students very well. Other 
hindrances to this project’s success included time required to do routine “housekeeping” 
work, such as culturing cells or running PCR gels. A team approach might significantly 
improve the potential for successful results. Therefore, based on my experiences, I would 
recommend that a project of this type in the future be completed either by two students or 
at least a two-year time period that would allow a “doubling up” on all fronts-- thereby 
increasing experimental frequency, decreasing time constraints and ensuring a successful 
outcome to contribute to the efforts to cure leukemia.
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